New Haven, CT – According to filings with the U.S. Securities and Exchange Commission, Artizan Biosciences is raising $10,877,922.00 in new funding. Sources indicate as part of senior management President, James Rosen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Artizan Biosciences

Artizan Biosciences, Inc. is a biotechnology company with a mission to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies. We are leveraging our proprietary IgA-SEQ technology platform to distinguish disease-driving bacteria from the intestinal microbiota with the goal of developing new and potentially curative treatments.

To learn more about Artizan Biosciences, visit http://artizanbiosciences.com/

Contact:
James Rosen, President
203-457-3484
https://www.linkedin.com/in/rosenjames/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved